chevron_leftBack
As of 24 April 2025, Genenta Science S.p.A. has a market cap of $70.05M USD, ranking #22711 globally and #195 in Italy. It ranks #2272 in the Healthcare sector, and #709 in the Biotechnology industry.
Key Stats
Market Cap
$70.05MUSD
Enterprise Value
$56.96MUSD
EBITDA (TTM)
-$10.06MUSD
Net Income (TTM)
-$9.23MUSD
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Pierluigi Paracchi
open_in_new
Employees
13
Founded
2014
IPO
15 Dec 2021
Website
genenta.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 2.3% | -1.3% | -7.7% | -4% | -23% | -3% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
GNTA
Genenta Science SPA ADR
ISIN: US36870W1009
Shares Out.:
Shares Outstanding:
18.29M1
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
3.83 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Genenta Science S.p.A.
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
